Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock sustained upside?

As Merck's blockbuster Keytruda drives massive revenue, you need to weigh its patent cliff risks against a robust oncology pipeline for U.S. and global investor decisions. Why does this matter now for your portfolio? ISIN: US58933Y1055

Merck & Co., Inc. stands as a pharmaceutical powerhouse, with its oncology franchise led by Keytruda generating the bulk of its revenue and positioning the stock as a defensive play for investors in the United States and across English-speaking markets worldwide. You face a classic biotech dilemma: a dominant drug facing generic competition in the coming years, balanced by promising pipeline candidates and strategic acquisitions. This report breaks down why Merck matters for your portfolio, focusing on validated business strengths, risks, and what to watch next.

Updated: 15.04.2026

By Elena Vargas, Senior Pharma Equity Analyst – Exploring how Merck's oncology leadership shapes long-term value for investors.

Merck's Core Business Model: Oncology at the Center

Merck & Co., Inc. operates a diversified pharmaceutical model centered on high-margin blockbuster drugs, particularly in oncology, vaccines, and hospital specialties. Keytruda, its PD-1 immunotherapy, accounts for over 40% of total sales, underscoring the company's reliance on this cash cow to fund R&D and dividends. You benefit from Merck's scale as a top global player, with operations spanning the United States, Europe, and emerging markets, delivering consistent revenue growth even in economic downturns.

The business model emphasizes innovation through internal R&D and partnerships, such as with Moderna on vaccines and Ridgeback Biotherapeutics on antivirals. This approach allows Merck to pivot from mature products like Januvia to next-generation therapies, maintaining a robust free cash flow profile that supports a 2.5% dividend yield attractive to income-focused investors. For U.S. readers, Merck's heavy reliance on domestic sales—about 50% of revenue—ties its fortunes closely to Medicare pricing reforms and FDA approvals.

Beyond oncology, vaccines like Gardasil prevent HPV-related cancers, adding defensive revenue streams less vulnerable to patent cliffs. Merck's strategy avoids over-diversification into low-margin generics, focusing instead on specialty drugs where pricing power endures. This model has delivered compounded annual revenue growth of around 7% over the past decade, making it a staple for long-term portfolios.

Key Products and Global Markets: Keytruda's Blockbuster Status

Keytruda (pembrolizumab) remains Merck's growth engine, approved for multiple cancers including lung, melanoma, and head-and-neck, with sales exceeding $25 billion annually in recent years. You see this drug's versatility driving adoption across community oncologists and major cancer centers in the U.S., where it captures over 50% market share in first-line non-small cell lung cancer treatments. Globally, Keytruda thrives in Europe and Japan, bolstered by label expansions that extend its market to earlier-stage diseases.

Gardasil, the HPV vaccine, generates steady demand, particularly in the U.S. and China, protecting against cervical cancer precursors and fueling herd immunity trends. Winrevair, a recent approval for pulmonary arterial hypertension, adds a new revenue pillar with peak sales potential in the billions, diversifying beyond immuno-oncology. Merck's animal health division, via Merck Animal Health, provides recession-resistant income from livestock and companion animal products worldwide.

In markets like the United States, pricing pressures from the Inflation Reduction Act cap upside, but volume growth from new indications offsets this. For investors across English-speaking regions, Merck's presence in Canada, the UK, and Australia ensures broad exposure to aging populations driving oncology demand. The company's focus on biologics positions it well in high-growth areas like antibody-drug conjugates.

Industry Drivers and Competitive Position

The oncology market expands rapidly due to aging demographics, rising cancer incidence, and advances in immunotherapy, where Merck holds a leading edge over rivals like Bristol Myers Squibb and Roche. Keytruda's combination therapies with chemotherapy or other immunotherapies solidify its frontline status, creating high switching costs for physicians. You appreciate Merck's R&D spend, around 25-30% of revenue, fueling a pipeline of 80+ programs targeting solid tumors and hematologic cancers.

Competition intensifies from biosimilars and next-gen therapies, but Merck counters with acquisitions like Acceleron Pharma for Winrevair and EyeBio for ophthalmology assets. In vaccines, Merck competes with Pfizer and GSK, yet Gardasil's efficacy and established guidelines maintain dominance. The company's cardiovascular entry via sotatercept challenges United Therapeutics, potentially disrupting that niche.

Strategic alliances, such as with Kelun-Biotech for ADCs in China, expand geographic reach without heavy capex. For U.S. investors, Merck's patent portfolio—averaging 15 years remaining on key assets—provides a moat, though generics loom post-2028 for Keytruda. Globally, regulatory harmonization aids faster approvals, enhancing Merck's position versus pure-play biotechs.

Investor Relevance in the United States and English-Speaking Markets

For you as a U.S. investor, Merck offers stability amid market volatility, with heavy weighting in S&P 500 health care ETFs and a dividend aristocrat status spanning decades. Domestic sales dominance means you're exposed to PBM negotiations and IRA drug price caps, yet oncology exemptions shield Keytruda somewhat. Across English-speaking markets like the UK, Canada, and Australia, universal healthcare systems favor cost-effective blockbusters, boosting Merck's reimbursement profiles.

Tax advantages from U.S. headquarters and R&D credits enhance after-tax returns for American portfolios. In a high-interest environment, Merck's low debt-to-equity ratio supports buybacks and special dividends, appealing to yield seekers. Global diversification mitigates U.S.-centric risks like litigation over past drugs like Vioxx echoes.

ESG factors matter increasingly; Merck scores high on access-to-medicines initiatives, resonating with institutional funds prevalent in English-speaking regions. You gain from Merck's role in pandemic preparedness, via molnupiravir and future vaccines, aligning with public health priorities post-COVID.

Analyst Views and Research Coverage

Reputable analysts from firms like Morningstar highlight Merck's wide economic moat driven by Keytruda's entrenchment, though recent evaluations place it among undervalued pharma names relative to fair value estimates in broad wide-moat screens. Coverage emphasizes pipeline derisking, with consensus leaning toward moderate growth post-patent cliff via new launches like Winrevair and Lynparza collaborations. Banks note steady dividend growth as a positive, balancing oncology risks with hospital acute care stability.

Strategic interpretations focus on M&A potential to refill the pipeline, with some seeing upside if Keytruda biosimilars face delays. Overall, views classify Merck as a hold-to-buy candidate for defensive portfolios, citing resilient margins around 40% gross and R&D efficiency. No recent downgrades signal confidence in execution amid competitive pressures.

Risks and Open Questions

The looming Keytruda patent expiry around 2028 poses the biggest risk, potentially eroding $20+ billion in sales as biosimilars enter, particularly in Europe first. You must monitor FDA litigation outcomes and label maintenance strategies to extend exclusivity. Pipeline failures, like past disappointments in Alzheimer's, could strain R&D returns if next-gen assets falter.

Pricing reforms in the U.S. under Medicare Part D changes cap revenue growth, while global reimbursement cuts in ex-U.S. markets add pressure. Competition from Opdivo combinations or emerging CAR-T therapies challenges market share. Open questions include M&A firepower post-Winrevair integration and success in non-oncology areas like cardiometabolic diseases.

Macro risks like inflation impacting trial costs or geopolitical tensions disrupting supply chains for biologics affect execution. For investors, diversification into earlier-stage bets via partnerships remains key, but binary trial outcomes create volatility.

What Should You Watch Next?

Track Keytruda Phase 3 readouts in adjuvant settings and combination trials, as positive data could extend lifecycle beyond 2030. Monitor Winrevair launch uptake, targeting 20-30% market share in PAH by year three. Upcoming earnings will reveal guidance on post-Keytruda growth and M&A plans.

For U.S. investors, watch IRA negotiations and Supreme Court rulings on drug pricing. Pipeline milestones like subcutaneous Keytruda or next-gen ADCs signal diversification success. Dividend hikes and buyback acceleration indicate confidence in cash flows.

Globally, China sales acceleration for Gardasil and Keytruda approvals in new indications bear watching. If biosimilar erosion proves slower than feared, Merck transforms from defensive hold to growth contender in your portfolio.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.